IP Library Granted Patent US 8,084,239
Granted Patent B2
US 8,084,239 · App. 12/430,554 · Granted Dec 27, 2011

Preparation of a therapeutic composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,239
App. No.
12/430,554
Granted
Dec 27, 2011
Kind
B2
Abstract

Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm.

Claims (14)

1. A method for producing a peptide-nucleic acid product comprising the steps of:

a) suspending about 35.0 grams of casein, about 17.1 grams of beef peptone, about 22.0 grams of ribonucleic acid (RNA), and about 3.25 grams of bovine serum albumin in about 2.5 liters of water;

b) adding about 11.75 ml of hydrochloric acid to the mixture from step a;

c) autoclaving the product from step b at about 9 lbs pressure and 200-230° F. until the RNA is completely digested;

d) cooling the product from step c to about 3-8° C.;

e) sequentially filtering the product from step d through a 2 micron filter, a 0.45 micron filter and a 0.2 micron filter;

f) diluting the product from step e with water to yield a final volume of about 5 liters;

g) adjusting the pH of the product from step f to a range of about 7.3 to 7.6;

h) filtering the product from step g through a second 0.2 micron filter; and

i) autoclaving the product from step h at 240° F. and 20-30 pounds pressure for about 30 minutes.

2. The method of claim 1 , wherein step e is repeated.

3. A product produced by the method of claim 1 .

4. A product produced by the method of claim 2 .

5. A pharmaceutical composition comprising a) the product of claim 3 ; and b) a pharmaceutically acceptable carrier.

Assignments (3)
MERGER Recorded Nov 8, 2011
From: BBM HOLDINGS, INC.
To: OHR PHARMACEUTICAL, INC.
Reel/Frame 027189/0679 →
FORECLOSURE BY THIRD PARTY Recorded Jun 16, 2009
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: BBM HOLDINGS, INC.
Reel/Frame 022832/0190 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2009
From: FRIEDLAND, BERNARD; HIRSCHMAN, SHALOM Z.; TARAPOREWALA, IRACH B.
To: ADVANCED VIRAL RESEARCH CORP.
Reel/Frame 022807/0934 →